Shots:

• Dare to receive up front- $20M as option exercise fee- $310M as commercial milestones- royalties on sales of the product along with access to Bayer's clinical and market capabilities and remain responsible for development & regulatory activities of Ovaprene
• Bayer to get exclusive right to commercialize Ovaprene in the US- once approved by the FDA. Dare is expected to file IDE for the therapy in H1’20 and the initiation of its clinical study in H2’20 following FDA’s review and clearance of the IDE
•  Ovaprene is an investigational hormone-free monthly vaginal contraceptive- currently in development for the prevention of pregnancy and if approved- will be the first monthly non-hormonal contraceptive therapy

Click here ­to­ read full press release/ article | Ref: Bayer  | Image: Dare Bioscience